Cargando…
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
Everolimus (RAD001, Afinitor(®) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic. Everolimus 10 mg daily achieves complete inhibition of its target at below the maximum tolerable dose for most patients. A phase III randomized placebo-controll...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880340/ https://www.ncbi.nlm.nih.gov/pubmed/20531964 |